Background More than 10 years have elapsed since human papillomavirus (HPV) vaccination
was implemented. We did a systematic review and meta-analysis of the population-level …

Infection with human papillomavirus (HPV) is recognized as one of the major causes of
infection-related cancer worldwide, as well as the causal factor in other diseases. Strong …

More than 120 different types of the human papillomavirus (HPV) have been isolated; >40 of
these types infect the epithelial lining of the anogenital tract and other mucosal areas. In the …

Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent
vaccine in preventing anogenital diseases associated with human papillomavirus (HPV…

Background Vulval and vaginal cancers among younger women are often related to infection
with human papillomavirus (HPV). These cancers are preceded by high-grade vulval …

BackgroundHuman papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18–related
cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in situ (AIS). …

BackgroundThe placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) MethodsWomen enrolled in the placebo arm (n=8800) …

Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …

BackgroundWe evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine
on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51…